Go to the list of all blogs
Allana's Avatar
published in Blogs
Jul 16, 2026
VIXY vs VXX: Two Specialized Vehicles for Short-Term Volatility Exposure

VIXY vs VXX: Two Specialized Vehicles for Short-Term Volatility Exposure

Key Takeaways

  • Both VIXY and VXX provide exposure to short-term VIX futures, targeting increases in expected S&P 500 volatility rather than equity ownership.
  • VIXY is structured as an ETF (commodity pool), while VXX is an ETN (exchange-traded note), introducing counterparty credit risk for the latter.
  • Expense ratios are competitive, with VIXY at 0.85% and VXX at 0.89%, reflecting the operational costs of futures roll strategies.
  • Neither ETF holds traditional equities or bonds; both maintain positions in near-term VIX futures contracts, leading to similar volatility sensitivity but potential differences in tracking and liquidity profiles.
  • These products serve as tactical tools for volatility hedging or speculation, with performance driven by futures curve dynamics such as contango rather than underlying company fundamentals.
  • Structural distinctions in legal form and issuer may influence long-term suitability depending on investor risk tolerance and platform considerations.

Introduction

ProShares VIX Short-Term Futures ETF (VIXY) and iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX) represent specialized vehicles for accessing equity market volatility. They do not compete as core equity holdings but offer alternative strategies for investors seeking to hedge against or capitalize on spikes in the CBOE Volatility Index (VIX). In the current market environment characterized by shifting macroeconomic conditions and periodic uncertainty, these ETFs provide distinct yet closely aligned pathways to short-term volatility exposure.

A Closer Look at VIXY

ProShares VIX Short-Term Futures ETF (VIXY) seeks investment results that correspond to the performance of the S&P 500 VIX Short-Term Futures Index before fees and expenses. The fund employs a futures-based strategy with no traditional equity or fixed-income holdings; positions consist of near-term VIX futures contracts. It operates as an ETF structured as a commodity pool. The expense ratio stands at 0.85%. Distinguishing features include daily rebalancing of futures positions to maintain targeted exposure and options availability for enhanced trading flexibility. When I reviewed comparable instruments recently, I also checked this using Tickeron’s AI Screener to see how the fund aligns with other volatility products.

A Closer Look at VXX

iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX) is designed to deliver returns linked to the S&P 500 VIX Short-Term Futures Index Total Return. Like its counterpart, it relies on short-term VIX futures without conventional portfolio holdings. The product is structured as an ETN, a senior unsecured debt obligation of the issuer. The expense ratio is 0.89%. Key characteristics include passive tracking of the volatility futures index with periodic rolls of expiring contracts and listing on major U.S. exchanges for liquidity.

Industry and Thematic Context

Both ETFs operate within the volatility trading and hedging segment of the broader derivatives and alternative investment landscape. Macroeconomic drivers such as interest rate policy shifts, geopolitical tensions, and economic data releases influence demand for volatility products. Regulatory oversight from bodies like the U.S. Securities and Exchange Commission (SEC) governs ETN structures, emphasizing issuer creditworthiness. Capital flows into these instruments often rise during periods of market stress, while contango in the VIX futures curve poses a structural headwind through negative roll yields over extended holding periods.

Performance and Positioning

In recent market cycles, both VIXY and VXX have exhibited high sensitivity to volatility spikes driven by sector rotations, earnings announcements, and macroeconomic surprises. Their futures-based construction leads to comparable responses to short-term VIX movements, though differences in expense ratios and structure may contribute to minor tracking variations. Relative positioning favors tactical deployment during elevated uncertainty, with performance influenced by the shape of the futures curve rather than traditional sector allocations.

Enhancing Research with AI Tools

In my own analysis workflow, I often rely on Tickeron’s AI-powered tools to cross-reference data points and identify comparable instruments more efficiently. Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening.

My Assessment

Based on structural efficiency, slightly lower expense ratio, and ETF format without ETN counterparty considerations, Tickeron’s AI would currently assign a modest probabilistic preference to ProShares VIX Short-Term Futures ETF (VIXY) for investors prioritizing cost and legal structure within this volatility niche, while acknowledging that both instruments share highly similar exposure profiles.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: VIXY, VXX

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Momentum Indicator for VIXY turns negative, indicating new downward trend

VIXY saw its Momentum Indicator move below the 0 level on July 31, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In of the 82 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for VIXY turned negative on August 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIXY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VIXY broke above its upper Bollinger Band on July 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for VIXY entered a downward trend on July 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VIXY advanced for three days, in of 194 cases, the price rose further within the following month. The odds of a continued upward trend are .

Industry description

The investment seeks investment results, before fees and expenses, that over time, match the performance of the S&P 500 VIX Short-Term Futures Index for a single day. The index seeks to offer exposure to market volatility through publicly traded futures markets and is designed to measure the implied volatility of the S&P 500 over 30 days in the future.
View a ticker or compare two or three
VIXY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Miscellaneous
Address
ProShares Trust II7501 WISCONSIN AVEBethesda
Phone
240-497-6400
Web
www.proshares.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.